Latest Renal Fibrosis News

Vectus Biosystems appoints Dr Tara Speranza as CEO and CTO to accelerate development of lead fibrosis drug VB0004 with performance-linked incentives.

Vectus Biosystems has completed the sale of its VB4-P5 renal fibrosis compound to Canadian biotech XORTX, receiving a near 10% equity stake and warrants. This move aligns with Vectus’ strategy to develop drug candidates to a stage attractive to partners while focusing on its lead compound VB0004.

Vectus Biosystems reports a narrowed half-year loss as it advances clinical drug VB0004 and nears a key asset sale to XORTX Therapeutics.

Vectus Biosystems is close to finalising a $4.3 million transaction with Canadian biotech XORTX Therapeutics, while actively pursuing licensing opportunities for its anti-fibrotic drug candidates amid cost reductions.

Vectus Biosystems has signed a binding agreement to sell its VB4-P5 renal fibrosis compound to Canadian biotech XORTX Therapeutics, while actively pursuing licensing opportunities for its lead drug VB0004 and others, particularly in China.

Vectus Biosystems has agreed to sell its VB4-P5 renal fibrosis compound to Canadian biotech XORTX Therapeutics for US$3 million in shares and warrants, gaining a strategic equity position while refocusing on its cardiovascular and fibrosis pipeline.